Ignite Creation Date:
2026-03-26 @ 3:21 PM
Ignite Modification Date:
2026-03-31 @ 4:35 PM
Study NCT ID:
NCT05250427
Status:
COMPLETED
Last Update Posted:
2022-06-14
First Post:
2022-02-11
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Awareness, Care & Treatment In Obesity Management - An Observation in Asia Pacific
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2026-03-25'}, 'conditionBrowseModule': {'meshes': [{'id': 'D009765', 'term': 'Obesity'}], 'ancestors': [{'id': 'D050177', 'term': 'Overweight'}, {'id': 'D044343', 'term': 'Overnutrition'}, {'id': 'D009748', 'term': 'Nutrition Disorders'}, {'id': 'D009750', 'term': 'Nutritional and Metabolic Diseases'}, {'id': 'D001835', 'term': 'Body Weight'}, {'id': 'D012816', 'term': 'Signs and Symptoms'}, {'id': 'D013568', 'term': 'Pathological Conditions, Signs and Symptoms'}]}}, 'protocolSection': {'designModule': {'studyType': 'OBSERVATIONAL', 'designInfo': {'timePerspective': 'CROSS_SECTIONAL', 'observationalModel': 'COHORT'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 12404}, 'patientRegistry': False}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2022-04-26', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2022-06', 'completionDateStruct': {'date': '2022-05-23', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2022-06-13', 'studyFirstSubmitDate': '2022-02-11', 'studyFirstSubmitQcDate': '2022-02-11', 'lastUpdatePostDateStruct': {'date': '2022-06-14', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2022-02-22', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2022-05-23', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Weight loss motivators for improving health of PLwO', 'timeFrame': 'At the time of survey response (Day 1)', 'description': 'Multi-select from defined list'}, {'measure': 'Weight loss barriers for improving health of PLwO', 'timeFrame': 'At the time of survey response (Day 1)', 'description': 'Multi-select from defined list'}, {'measure': 'Weight loss management for improving health of PLwO', 'timeFrame': 'At the time of survey response (Day 1)', 'description': 'Multi-select from defined list'}, {'measure': 'Weight loss responsibility for improving health of PLwO', 'timeFrame': 'At the time of survey response (Day 1)', 'description': 'Multi-select from defined list'}, {'measure': 'Proportion of PLwO who made serious weight loss effort', 'timeFrame': 'At the time of survey response (Day 1)', 'description': 'Number of weight loss efforts; percentage of patients'}, {'measure': 'Response to weight loss discussions', 'timeFrame': 'At the time of survey response (Day 1)', 'description': 'Single select from defined list'}, {'measure': 'Attitudes towards obesity and weight management and Interactions of PLwOs with HCPs', 'timeFrame': 'At the time of survey response (Day 1)', 'description': '5-point Likert scales'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'conditions': ['Obesity']}, 'descriptionModule': {'briefSummary': 'ACTION APAC is a cross-sectional, observational, descriptive, and exploratory survey-based study without collection of laboratory data. The study is not related to any specific treatment options or pharmaceutical product. Collection of data will be performed via quantitative online survey by a third-party vendor through existing databases/panels in APAC region.\n\nThe goal of this study is to provide insights to drive awareness around the needs of People Living with Obesity (PLwO) and Health Care Professionals (HCPs) involved in obesity treatment and management.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'samplingMethod': 'NON_PROBABILITY_SAMPLE', 'studyPopulation': 'The respondent population will include people living with obesity (PLwO) and health care professionals (HCPs) involved in obesity treatment and management.', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion criteria:\n\nPeople Living with Obesity\n\n1. Informed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol).\n2. Male or female, aged above or equal to 18 years at the time of signing informed consent\n3. Lives in one of the target countries\n4. Current BMI of at least 25 kg/m\\^2 for all countries (except Singapore which has current BMI 27 kg/m\\^2) based on self-reported height and weight\n\nHealth Care Professionals\n\n1. Informed consent before any study related activities (study-related activities are any procedure related to recording/collection of data according to protocol)\n2. Male or female, aged greater than or equal to 18 years at the time of signing informed consent.\n3. Physician\n4. Primary Care Providers (PCPs) whose specialty is Family practice, General practice, Internal Medicine\n5. Non-PCP Specialties whose specialty is Endocrinologist, Cardiologist, Gastroenterologist, Obstetrics/Gynaecologist, Bariatrics/Obesity Medicine, Nutrition Specialist (physician) Orthopaedist, Aesthetics Medicine\n6. Specialty is not surgeon (including bariatric or plastic surgeon)\n7. Practices in the target countries\n8. In clinical practice for at least 2 years\n9. Spends at least 50% time in direct patient care\n10. Has seen at least 100 patients in past month\n11. Has seen at least 10 patients in past month who have obesity defined as: a patient with a BMI greater than or equal to 25 kg/m\\^2 for all countries (except Singapore which has current greater than or equal to BMI 27 kg/m\\^2) with or without comorbidities.\n\nExclusion criteria:\n\nPeople Living with obesity\n\n1. Previous participation in this study. Participation is defined as having given online consent in this study\n2. Currently pregnant\n3. Participates in intense fitness or body building programs\n4. Has had significant, unintentional weight loss (due to major injury, illness, etc) in the past 6 months\n5. Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation\n\nHealth Care Providers\n\n1. Previous participation in this study. Participation is defined as having given informed consent in this study.\n2. Unwillingness, inability, or language barriers precluding adequate understanding or cooperation'}, 'identificationModule': {'nctId': 'NCT05250427', 'acronym': 'ACTION-APAC', 'briefTitle': 'Awareness, Care & Treatment In Obesity Management - An Observation in Asia Pacific', 'organization': {'class': 'INDUSTRY', 'fullName': 'Novo Nordisk A/S'}, 'officialTitle': 'Awareness, Care & Treatment In Obesity Management - An Observation in Asia Pacific', 'orgStudyIdInfo': {'id': 'DAS-006'}, 'secondaryIdInfos': [{'id': 'U1111-1266-5484', 'type': 'OTHER', 'domain': 'World Health Organization (WHO)'}]}, 'armsInterventionsModule': {'armGroups': [{'label': 'People / Person Living with Obesity (PLwO)', 'description': 'From online, general population consumer panels', 'interventionNames': ['Other: No treatment given']}, {'label': 'Health Care Professionals (HCPs)', 'description': 'HCPs treating people who have obesity', 'interventionNames': ['Other: No treatment given']}], 'interventions': [{'name': 'No treatment given', 'type': 'OTHER', 'description': 'No treatment given', 'armGroupLabels': ['Health Care Professionals (HCPs)', 'People / Person Living with Obesity (PLwO)']}]}, 'contactsLocationsModule': {'locations': [{'city': 'Dhaka', 'country': 'Bangladesh', 'facility': 'Novo Nordisk Investigational Site', 'geoPoint': {'lat': 23.7104, 'lon': 90.40744}}, {'city': 'Bangalore', 'country': 'India', 'facility': 'Novo Nordisk Investigational Site', 'geoPoint': {'lat': 12.97194, 'lon': 77.59369}}, {'city': 'Jakarta', 'country': 'Indonesia', 'facility': 'Novo Nordisk Investigational Site', 'geoPoint': {'lat': -6.21462, 'lon': 106.84513}}, {'city': 'Kuala Lumpur', 'country': 'Malaysia', 'facility': 'Novo Nordisk Investigational Site', 'geoPoint': {'lat': 3.1412, 'lon': 101.68653}}, {'city': 'Karachi', 'country': 'Pakistan', 'facility': 'Novo Nordisk Investigational Site', 'geoPoint': {'lat': 24.8608, 'lon': 67.0104}}, {'city': 'Manila', 'country': 'Philippines', 'facility': 'Novo Nordisk Investigational Site', 'geoPoint': {'lat': 14.6042, 'lon': 120.9822}}, {'city': 'Singapore', 'country': 'Singapore', 'facility': 'Novo Nordisk Investigational Site', 'geoPoint': {'lat': 1.28967, 'lon': 103.85007}}, {'city': 'Bangkok', 'country': 'Thailand', 'facility': 'Novo Nordisk Investigational Site', 'geoPoint': {'lat': 13.75398, 'lon': 100.50144}}, {'city': 'Ho Chi Minh City', 'country': 'Vietnam', 'facility': 'Novo Nordisk Investigational Site', 'geoPoint': {'lat': 10.82302, 'lon': 106.62965}}], 'overallOfficials': [{'name': 'Clinical Transparency (dept. 2834)', 'role': 'STUDY_DIRECTOR', 'affiliation': 'Novo Nordisk A/S'}]}, 'ipdSharingStatementModule': {'url': 'http://novonordisk-trials.com', 'ipdSharing': 'YES', 'description': 'According to the Novo Nordisk disclosure commitment on novonordisk-trials.com'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Novo Nordisk A/S', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}